BioLineRx Ltd. (NASDAQ: BLRX) and Hemispherian AS announced the first patient has been dosed in a Phase 1/2a clinical trial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE